LONDON, Oct. 28, 2024 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2024 financial results and operational highlights before open of US markets on Tuesday, November 12, 2024.
Management will host a conference call and webcast at 8:30 am EDT/1:30 pm BST to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.
A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.
Contact:
Olivia Manser
+44 (0) 7780 471568
o.manser@autolus.com
Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com
Susan A. Noonan
S.A. Noonan Communications
+1-917-513-5303
susan@sanoonan.com
LUXEMBOURG, April 21, 2025 (GLOBE NEWSWIRE) -- In response to a number of media speculations…
Toronto, April 21, 2025 (GLOBE NEWSWIRE) -- Ceylon Graphite Corp. (TSXV: CYL) (“Ceylon” or the…
Engineering firm’s longevity built on employee strength and innovationOLATHE, Kan., April 21, 2025 (GLOBE NEWSWIRE)…
Santa Clara, April 21, 2025 (GLOBE NEWSWIRE) -- Santa Clara, California - In recent developments,…
The Utility Token Debut to Boost Community Interaction, Exclusive Access, and Web3-Powered Gaming InnovationsDubai, UAE,…
CampervanHire.Com offers RV, camper van, and motorhome rentals for travelers.Stockport , April 21, 2025 (GLOBE…
This website uses cookies.